Lexicon rises with advance of key drug

optionMONSTER

Drug Progresses to Final Stage of Testing

Lexicon Pharmaceuticals reported positive data for its drug that treats carcinoid tumors. It's now moving from Phase 2 trials to Phase 3 trials, sending LXRX higher by 13 percent in the premarket.

Infosys Sees Weaker Profit

Infosys now expect full-year earnings of $2.97 a share, versus its previous forecast of $3.03.The outsourcing company also failed to raise it revenue guidance as analysts had hoped. INFY drops 5 percent in early trading.

J.B. Hunt Revenue Beats Expectations

J.B. Hunt Transport Services had third-quarter revenue of $1.30 billion, beating the $1.28 billion estimate. Profit missed expectations, but investors are focusing on that strong top-line number and sending JBHT higher by about 5 percent in the premarket.

Weak PC Market Drags on AMD

Advanced Micro Devices preannounced that third-quarter revenue fell by about 10 percent. It had previously forecast a decline of no more than 4 percent. Management cited a weakening PC market, and AMD is lower by 9 percent in the pre.



More From optionMONSTER
View Comments (0)